You are here: Industry Insights > Arch Biopartners

News List

University of Calgary Joins Trial of LSALT Peptide for Complications in Hospitalized COVID-19 Patients americanpharmaceuticalreview
January 12, 2021
Arch Biopartners announced the University of Calgary Cumming School of Medicine has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications ...
First Patient Dosed in Trial to Treat Complications in COVID-19 americanpharmaceuticalreview
October 22, 2020
Arch Biopartners has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to ...
Arch Biopartners to Proceed with Metablok Trial for COVID-19 americanpharmaceuticalreview
June 28, 2020
Arch Biopartners announced the U.S. Food and Drug Administration (FDA) has granted permission to the Company to proceed with a Phase II trial in the U.S. for its lead drug Metablok (LSALT peptide) to prevent acute lung and kidney injury experienced by ...
Arch Biopartners Expands Primary Endpoint of COVID-19 Trial americanpharmaceuticalreview
May 26, 2020
Arch Biopartners has expanded the primary endpoint of the Phase II human trial for its lead drug LSALT peptide (Metablok) to prevent organ inflammation and injury experienced by patients with COVID-19.
Arch Biopartners' lead anti-bacterial drug candidate to enter investigator-sponsored Phase I human t cphi-online
April 17, 2017
AB569, which consists of two active ingredients, sodium nitrite and EDTA, has a novel mechanism of action that differs from that of antibiotics.